Reducing Treatment Burden and
Improving Outcomes in Neovascular Age-Related Macular Degeneration (nAMD): What
Managed Care Needs to Know about Emerging Therapies
medical education activity sponsored by NAMCP and AAMCN
series will provide critical updates on the advances in immunotherapies,
how to translate the most recent data into clinical and administrative practice.
These are archives of live webinars held between November 13 to November 19,
If you participated in any of the live webinars, you are not eligible to claim
credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.
Each session has its own specific valid dates
This series is supported by an educational grant
from Novartis Pharmaceuticals Corporation.
This activity is intended for healthcare professionals practicing in managed
CME/CNE: Complete the pre-test, listen to the audio and view the slides,
complete the post test, complete the evaluation form and hit submit. You will be
asked to enter your name and email address on the pre-test, evaluation and
post-test. If you close your internet browser without completing the post test,
you will have ONE more opportunity to complete. A score of 70% must be achieved
on the post test to receive continuing education credits. If you do not pass the
post test after two attempts, you will not be eligible to try again. Once you
complete the evaluation form and score 70% or higher on your post test, you will
automatically be given your certificate.
Age-related macular degeneration (AMD) is a leading cause of severe vision loss
among people aged 50 years and older. It is estimated that nearly 3 million
individuals in the US will develop AMD by 2020 and that the prevalence will
continue to increase due to the aging population. Neovascular, or "wet" AMD
imposes a high burden on patients, eye care providers and payers alike, as
optimal visual outcomes have been contingent on regular, ongoing treatment.
Fortunately for patients with nAMD, new treatments have arrived or are on the
horizon. This webinar series will feature strategies to reduce treatment burden
and improve outcomes as experts will discuss the current burden of treatment,
evaluate new dosing and administration schedules, as well as review the safety
and efficacy of therapies in late-stage development.